| Published Application/Species/Sample/Dilution | Reference |
|---|
- immunocytochemistry knockout validation; human; loading ...; fig 2c
| Burr M, Sparbier C, Chan Y, Williamson J, Woods K, Beavis P, et al. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature. 2017;549:101-105 pubmed publisher |
- flow cytometry; human; loading ...
| Li Z, Zhang H, Huang Y, Huang J, Sun P, Zhou N, et al. Autophagy deficiency promotes triple-negative breast cancer resistance to T cell-mediated cytotoxicity by blocking tenascin-C degradation. Nat Commun. 2020;11:3806 pubmed publisher |
- western blot; human; 1:1000; loading ...; fig 3c
| Wang S, Yao F, Lu X, Li Q, Su Z, Lee J, et al. Temozolomide promotes immune escape of GBM cells via upregulating PD-L1. Am J Cancer Res. 2019;9:1161-1171 pubmed |
- flow cytometry; human; loading ...; fig 3b
| Tong A, Hashem H, Eid S, Allen F, Kingsley D, Huang A. Adoptive natural killer cell therapy is effective in reducing pulmonary metastasis of Ewing sarcoma. Oncoimmunology. 2017;6:e1303586 pubmed publisher |
- flow cytometry; human; tbl 3
| Fromm J, Thomas A, Wood B. Characterization and Purification of Neoplastic Cells of Nodular Lymphocyte Predominant Hodgkin Lymphoma from Lymph Nodes by Flow Cytometry and Flow Cytometric Cell Sorting. Am J Pathol. 2017;187:304-317 pubmed publisher |
- blocking or activating experiments; mouse; loading ...; fig 10
| Saha A, O Connor R, Thangavelu G, Lovitch S, Dandamudi D, Wilson C, et al. Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality. J Clin Invest. 2016;126:2642-60 pubmed publisher |
- blocking or activating experiments; human; fig 3
- flow cytometry; human
| Deisting W, Raum T, Kufer P, Baeuerle P, Münz M. Impact of Diverse Immune Evasion Mechanisms of Cancer Cells on T Cells Engaged by EpCAM/CD3-Bispecific Antibody Construct AMG 110. PLoS ONE. 2015;10:e0141669 pubmed publisher |
| Akhmetzyanova I, Drabczyk M, Neff C, Gibbert K, Dietze K, Werner T, et al. PD-L1 Expression on Retrovirus-Infected Cells Mediates Immune Escape from CD8+ T Cell Killing. PLoS Pathog. 2015;11:e1005224 pubmed publisher |
- immunohistochemistry - frozen section; human; 1:50; fig 2
| Gulati N, Suárez Fariñas M, Correa Da Rosa J, Krueger J. Psoriasis is characterized by deficient negative immune regulation compared to transient delayed-type hypersensitivity reactions. F1000Res. 2015;4:149 pubmed publisher |
- western blot; mouse; 1:500
| Yoon K, Byun S, Kwon E, Hwang S, Chu K, Hiraki M, et al. Control of signaling-mediated clearance of apoptotic cells by the tumor suppressor p53. Science. 2015;349:1261669 pubmed publisher |
- blocking or activating experiments; human; fig 4
| Tian X, Zhang A, Qiu C, Wang W, Yang Y, Qiu C, et al. The upregulation of LAG-3 on T cells defines a subpopulation with functional exhaustion and correlates with disease progression in HIV-infected subjects. J Immunol. 2015;194:3873-82 pubmed publisher |
- flow cytometry; human; fig 5
| Severson J, Serracino H, Mateescu V, Raeburn C, McIntyre R, Sams S, et al. PD-1+Tim-3+ CD8+ T Lymphocytes Display Varied Degrees of Functional Exhaustion in Patients with Regionally Metastatic Differentiated Thyroid Cancer. Cancer Immunol Res. 2015;3:620-30 pubmed publisher |
| Hautefort A, Girerd B, Montani D, Cohen Kaminsky S, Price L, Lambrecht B, et al. T-helper 17 cell polarization in pulmonary arterial hypertension. Chest. 2015;147:1610-1620 pubmed publisher |
- immunohistochemistry; human
| Gadiot J, Hooijkaas A, Kaiser A, Van Tinteren H, van Boven H, Blank C. Overall survival and PD-L1 expression in metastasized malignant melanoma. Cancer. 2011;117:2192-201 pubmed publisher |
- immunohistochemistry - frozen section; human; fig 1
- flow cytometry; human
| Raptopoulou A, Bertsias G, Makrygiannakis D, Verginis P, Kritikos I, Tzardi M, et al. The programmed death 1/programmed death ligand 1 inhibitory pathway is up-regulated in rheumatoid synovium and regulates peripheral T cell responses in human and murine arthritis. Arthritis Rheum. 2010;62:1870-80 pubmed publisher |
- blocking or activating experiments; human; 10 ug/ml; fig 6
| Trabattoni D, Saresella M, Pacei M, Marventano I, Mendozzi L, Rovaris M, et al. Costimulatory pathways in multiple sclerosis: distinctive expression of PD-1 and PD-L1 in patients with different patterns of disease. J Immunol. 2009;183:4984-93 pubmed publisher |
- flow cytometry; human; tbl 2
| Laudanski K, De A, Miller Graziano C. Exogenous heat shock protein 27 uniquely blocks differentiation of monocytes to dendritic cells. Eur J Immunol. 2007;37:2812-24 pubmed |
| Lellahi S, Azeem W, Hua Y, Gabriel B, Paulsen Rye K, Reikvam H, et al. GM-CSF, Flt3-L and IL-4 affect viability and function of conventional dendritic cell types 1 and 2. Front Immunol. 2022;13:1058963 pubmed publisher |
| Iraqi M, Bolel P, Sarkar R, Bhattacharya B, Abu Ahmad M, Edri A, et al. NKp44-Derived Peptide Used in Combination Stimulates Antineoplastic Efficacy of Targeted Therapeutic Drugs. Int J Mol Sci. 2022;23: pubmed publisher |
| Madhi H, Lee J, Choi Y, Li Y, Kim M, Choi Y, et al. FOXM1 Inhibition Enhances the Therapeutic Outcome of Lung Cancer Immunotherapy by Modulating PD-L1 Expression and Cell Proliferation. Adv Sci (Weinh). 2022;9:e2202702 pubmed publisher |
| Reda M, Ngamcherdtrakul W, Nelson M, Siriwon N, Wang R, Zaidan H, et al. Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment. Nat Commun. 2022;13:4261 pubmed publisher |
| Xu W, Liu W, Anwaier A, Tian X, Su J, Shi G, et al. Deciphering the role of miR-187-3p/LRFN1 axis in modulating progression, aerobic glycolysis and immune microenvironment of clear cell renal cell carcinoma. Discov Oncol. 2022;13:59 pubmed publisher |
| Munoz O, Banga R, Schelling R, Procopio F, Mastrangelo A, Nortier P, et al. Active PD-L1 incorporation within HIV virions functionally impairs T follicular helper cells. PLoS Pathog. 2022;18:e1010673 pubmed publisher |
| Bajor M, Graczyk Jarzynka A, Marhelava K, Burdzińska A, Muchowicz A, Góral A, et al. PD-L1 CAR effector cells induce self-amplifying cytotoxic effects against target cells. J Immunother Cancer. 2022;10: pubmed publisher |
| Tan Y, Xu Q, Wu Z, Zhang W, Li B, Zhang B, et al. Overexpression of PD-L1 is an Independent Predictor for Recurrence in HCC Patients Who Receive Sorafenib Treatment After Surgical Resection. Front Oncol. 2021;11:783335 pubmed publisher |
| Ravindran Menon D, Li Y, Yamauchi T, Osborne D, Vaddi P, Wempe M, et al. EGCG Inhibits Tumor Growth in Melanoma by Targeting JAK-STAT Signaling and Its Downstream PD-L1/PD-L2-PD1 Axis in Tumors and Enhancing Cytotoxic T-Cell Responses. Pharmaceuticals (Basel). 2021;14: pubmed publisher |
| Mirzaei R, Gordon A, Zemp F, Kumar M, Sarkar S, Luchman H, et al. PD-1 independent of PD-L1 ligation promotes glioblastoma growth through the NFκB pathway. Sci Adv. 2021;7:eabh2148 pubmed publisher |
| Lai C, Tseng P, Chen C, Satria R, Wang Y, Lin C. Different Induction of PD-L1 (CD274) and PD-1 (CD279) Expression in THP-1-Differentiated Types 1 and 2 Macrophages. J Inflamm Res. 2021;14:5241-5249 pubmed publisher |
| Mann J, Ludwig M, Kulkarni A, Scheftz E, Murray I, Zhai J, et al. Microbe-Mediated Activation of Toll-like Receptor 2 Drives PDL1 Expression in HNSCC. Cancers (Basel). 2021;13: pubmed publisher |
| Bamodu O, Wang Y, Yeh C, Ho C, Chiang Y, Kao W, et al. Concomitant High Apoptosis Inhibitor of Macrophage (AIM) and Low Prostate-Specific Antigen (PSA) Indicates Activated T Cell-Mediated Anticancer Immunity, Enhance Sensitivity to Pembrolizumab, and Elicit Good Prognosis in Prostate Cancer. Biomedicines. 2021;9: pubmed publisher |
| Carbotti G, Dozin B, Martini S, Giordano C, Scordamaglia F, Croce M, et al. IL-27 Mediates PD-L1 Expression and Release by Human Mesothelioma Cells. Cancers (Basel). 2021;13: pubmed publisher |
| Asano T, Boisson B, Onodi F, Matuozzo D, Moncada Velez M, Maglorius Renkilaraj M, et al. X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19. Sci Immunol. 2021;6: pubmed publisher |
| Zhang X, Huang X, Xu J, Li E, Lao M, Tang T, et al. NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1. Nat Commun. 2021;12:4536 pubmed publisher |
| Castro Gutierrez R, Alkanani A, Mathews C, Michels A, Russ H. Protecting Stem Cell Derived Pancreatic Beta-Like Cells From Diabetogenic T Cell Recognition. Front Endocrinol (Lausanne). 2021;12:707881 pubmed publisher |
| Spangenberg S, Zavareh R, Lairson L. Protocol for high-throughput compound screening using flow cytometry in THP-1 cells. STAR Protoc. 2021;2:100400 pubmed publisher |
| Chen H, Li M, Ng N, Yu E, Bujarski S, Yin Z, et al. Ruxolitinib reverses checkpoint inhibition by reducing programmed cell death ligand-1 (PD-L1) expression and increases anti-tumour effects of T cells in multiple myeloma. Br J Haematol. 2021;192:568-576 pubmed publisher |
| Oulès B, Philippeos C, Segal J, Tihy M, Vietri Rudan M, Cujba A, et al. Contribution of GATA6 to homeostasis of the human upper pilosebaceous unit and acne pathogenesis. Nat Commun. 2020;11:5067 pubmed publisher |
| Du L, Lee J, Jiang H, Wang C, Wang S, Zheng Z, et al. β-Catenin induces transcriptional expression of PD-L1 to promote glioblastoma immune evasion. J Exp Med. 2020;217: pubmed publisher |
| Heinz L, Lee J, Kapoor U, Kartnig F, Sedlyarov V, Papakostas K, et al. TASL is the SLC15A4-associated adaptor for IRF5 activation by TLR7-9. Nature. 2020;581:316-322 pubmed publisher |
| Cui B, Chen J, Luo M, Wang L, Chen H, Kang Y, et al. Protein kinase D3 regulates the expression of the immunosuppressive protein, PD‑L1, through STAT1/STAT3 signaling. Int J Oncol. 2020;56:909-920 pubmed publisher |
| Neuwelt A, Kimball A, Johnson A, Arnold B, Bullock B, Kaspar R, et al. Cancer cell-intrinsic expression of MHC II in lung cancer cell lines is actively restricted by MEK/ERK signaling and epigenetic mechanisms. J Immunother Cancer. 2020;8: pubmed publisher |
| Zhao Y, Lee C, Lin C, Gassen R, Xu X, Huang Z, et al. PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways. Immunity. 2019;51:1059-1073.e9 pubmed publisher |
| Dötzer K, Schlüter F, Schoenberg M, Bazhin A, von Koch F, Schnelzer A, et al. Immune Heterogeneity Between Primary Tumors and Corresponding Metastatic Lesions and Response to Platinum Therapy in Primary Ovarian Cancer. Cancers (Basel). 2019;11: pubmed publisher |
| Baruah P, Bullenkamp J, Wilson P, Lee M, Kaski J, Dumitriu I. TLR9 Mediated Tumor-Stroma Interactions in Human Papilloma Virus (HPV)-Positive Head and Neck Squamous Cell Carcinoma Up-Regulate PD-L1 and PD-L2. Front Immunol. 2019;10:1644 pubmed publisher |
| Musielak B, Kocik J, Skalniak L, Magiera Mularz K, Sala D, Czub M, et al. CA-170 - A Potent Small-Molecule PD-L1 Inhibitor or Not?. Molecules. 2019;24: pubmed publisher |
| Celis Gutierrez J, Blattmann P, Zhai Y, Jarmuzynski N, Ruminski K, Gregoire C, et al. Quantitative Interactomics in Primary T Cells Provides a Rationale for Concomitant PD-1 and BTLA Coinhibitor Blockade in Cancer Immunotherapy. Cell Rep. 2019;27:3315-3330.e7 pubmed publisher |
| Brodska B, Otevrelova P, Salek C, Fuchs O, Gasova Z, Kuzelova K. High PD-L1 Expression Predicts for Worse Outcome of Leukemia Patients with Concomitant NPM1 and FLT3 Mutations. Int J Mol Sci. 2019;20: pubmed publisher |
| Nakayama Y, Mimura K, Tamaki T, Shiraishi K, Kua L, Koh V, et al. Phospho‑STAT1 expression as a potential biomarker for anti‑PD‑1/anti‑PD‑L1 immunotherapy for breast cancer. Int J Oncol. 2019;54:2030-2038 pubmed publisher |
| Mitchell L, Yagiz K, Hofacre A, Viaud S, Munday A, Espinoza F, et al. PD-L1 checkpoint blockade delivered by retroviral replicating vector confers anti-tumor efficacy in murine tumor models. Oncotarget. 2019;10:2252-2269 pubmed publisher |
| Poggio M, Hu T, Pai C, Chu B, BELAIR C, Chang A, et al. Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory. Cell. 2019;177:414-427.e13 pubmed publisher |
| Pei X, Fan X, Zhang H, Duan H, Xu C, Xie B, et al. Low frequency, weak MCP-1 secretion and exhausted immune status of peripheral monocytes were associated with progression of severe enterovirus A71-infected hand, foot and mouth disease. Clin Exp Immunol. 2019;196:353-363 pubmed publisher |
| Xu L, Zhang Y, Tian K, Chen X, Zhang R, Mu X, et al. Apigenin suppresses PD-L1 expression in melanoma and host dendritic cells to elicit synergistic therapeutic effects. J Exp Clin Cancer Res. 2018;37:261 pubmed publisher |
| Guo X, Jiang H, Shi B, Zhou M, Zhang H, Shi Z, et al. Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma. Front Pharmacol. 2018;9:1118 pubmed publisher |
| Dijkstra K, Cattaneo C, Weeber F, Chalabi M, van de Haar J, Fanchi L, et al. Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids. Cell. 2018;174:1586-1598.e12 pubmed publisher |
| Zhao Y, Harrison D, Song Y, Ji J, Huang J, Hui E. Antigen-Presenting Cell-Intrinsic PD-1 Neutralizes PD-L1 in cis to Attenuate PD-1 Signaling in T Cells. Cell Rep. 2018;24:379-390.e6 pubmed publisher |
| Versteven M, Van den Bergh J, Broos K, Fujiki F, Campillo Davó D, De Reu H, et al. A versatile T cell-based assay to assess therapeutic antigen-specific PD-1-targeted approaches. Oncotarget. 2018;9:27797-27808 pubmed publisher |
| Martin A, Nirschl C, Polanczyk M, Bell W, Nirschl T, Harris Bookman S, et al. PD-L1 expression in medulloblastoma: an evaluation by subgroup. Oncotarget. 2018;9:19177-19191 pubmed publisher |
| Zhang J, Cao D, Yu S, Chen L, Wei D, Shen C, et al. Amphotericin B suppresses M2 phenotypes and B7-H1 expression in macrophages to prevent Raji cell proliferation. BMC Cancer. 2018;18:467 pubmed publisher |
| Narasimhan P, Akabas L, Tariq S, Huda N, Bennuru S, Sabzevari H, et al. Similarities and differences between helminth parasites and cancer cell lines in shaping human monocytes: Insights into parallel mechanisms of immune evasion. PLoS Negl Trop Dis. 2018;12:e0006404 pubmed publisher |
| Sun C, Lan P, Han Q, Huang M, Zhang Z, Xu G, et al. Oncofetal gene SALL4 reactivation by hepatitis B virus counteracts miR-200c in PD-L1-induced T cell exhaustion. Nat Commun. 2018;9:1241 pubmed publisher |
| Zhang L, Xu L, Zhu J, Li J, Xue B, Gao J, et al. ATM‑JAK‑PD‑L1 signaling pathway inhibition decreases EMT and metastasis of androgen‑independent prostate cancer. Mol Med Rep. 2018;17:7045-7054 pubmed publisher |
| Wentink M, Mueller Y, Dalm V, Driessen G, van Hagen P, van Montfrans J, et al. Exhaustion of the CD8+ T Cell Compartment in Patients with Mutations in Phosphoinositide 3-Kinase Delta. Front Immunol. 2018;9:446 pubmed publisher |
| Tamosiuniene R, Manouvakhova O, Mésange P, Saito T, Qian J, Sanyal M, et al. Dominant Role for Regulatory T Cells in Protecting Females Against Pulmonary Hypertension. Circ Res. 2018;122:1689-1702 pubmed publisher |
| Zheng B, Ren T, Huang Y, Sun K, Wang S, Bao X, et al. PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse. J Hematol Oncol. 2018;11:16 pubmed publisher |
| Witt D, Donson A, Amani V, Moreira D, Sanford B, Hoffman L, et al. Specific expression of PD-L1 in RELA-fusion supratentorial ependymoma: Implications for PD-1-targeted therapy. Pediatr Blood Cancer. 2018;65:e26960 pubmed publisher |
| Coelho M, de Carné Trécesson S, Rana S, Zecchin D, Moore C, Molina Arcas M, et al. Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA. Immunity. 2017;47:1083-1099.e6 pubmed publisher |
| Dimitrov V, Bouttier M, Boukhaled G, Salehi Tabar R, Avramescu R, Memari B, et al. Hormonal vitamin D up-regulates tissue-specific PD-L1 and PD-L2 surface glycoprotein expression in humans but not mice. J Biol Chem. 2017;292:20657-20668 pubmed publisher |
| Cao J, Brouwer N, Richards K, Marinkovic M, van Duinen S, Hurkmans D, et al. PD-L1/PD-1 expression and tumor-infiltrating lymphocytes in conjunctival melanoma. Oncotarget. 2017;8:54722-54734 pubmed publisher |
| Patel S, Sanjana N, Kishton R, Eidizadeh A, Vodnala S, Cam M, et al. Identification of essential genes for cancer immunotherapy. Nature. 2017;548:537-542 pubmed publisher |
| Layer J, Kronmüller M, Quast T, van den Boorn Konijnenberg D, Effern M, Hinze D, et al. Amplification of N-Myc is associated with a T-cell-poor microenvironment in metastatic neuroblastoma restraining interferon pathway activity and chemokine expression. Oncoimmunology. 2017;6:e1320626 pubmed publisher |
| Lin A, Twitty C, Burnett R, Hofacre A, Mitchell L, Espinoza F, et al. Retroviral Replicating Vector Delivery of miR-PDL1 Inhibits Immune Checkpoint PDL1 and Enhances Immune Responses In Vitro. Mol Ther Nucleic Acids. 2017;6:221-232 pubmed publisher |
| Hock B, MacPherson S, McKenzie J. Idelalisib and caffeine reduce suppression of T cell responses mediated by activated chronic lymphocytic leukemia cells. PLoS ONE. 2017;12:e0172858 pubmed publisher |
| Lazar Molnar E, Scandiuzzi L, Basu I, Quinn T, Sylvestre E, Palmieri E, et al. Structure-guided development of a high-affinity human Programmed Cell Death-1: Implications for tumor immunotherapy. EBioMedicine. 2017;17:30-44 pubmed publisher |
| Zhu J, Chen H, Huang X, Jiang S, Yang Y. Ly6Chi monocytes regulate T cell responses in viral hepatitis. JCI Insight. 2016;1:e89880 pubmed publisher |
| Davies L, Heldring N, Kadri N, Le Blanc K. Mesenchymal Stromal Cell Secretion of Programmed Death-1 Ligands Regulates T Cell Mediated Immunosuppression. Stem Cells. 2017;35:766-776 pubmed publisher |
| Wang X, Teng F, Kong L, Yu J. PD-L1 expression in human cancers and its association with clinical outcomes. Onco Targets Ther. 2016;9:5023-39 pubmed publisher |
| Tang Z, Hao Y, Zhang E, Xu C, Zhou Y, Zheng X, et al. CD28 family of receptors on T cells in chronic HBV infection: Expression characteristics, clinical significance and correlations with PD-1 blockade. Mol Med Rep. 2016;14:1107-16 pubmed publisher |
| Schaut R, Lamb I, Toepp A, Scott B, Mendes Aguiar C, Coutinho J, et al. Regulatory IgDhi B Cells Suppress T Cell Function via IL-10 and PD-L1 during Progressive Visceral Leishmaniasis. J Immunol. 2016;196:4100-9 pubmed publisher |
| Zhang J, Wang C, Zhang P, Wang X, Chen J, Yang J, et al. Expression of programmed death 1 ligand 1 on periodontal tissue cells as a possible protective feedback mechanism against periodontal tissue destruction. Mol Med Rep. 2016;13:2423-30 pubmed publisher |
| Rodrigues C, Ferreira A, Pinho M, de Moraes C, Bergami Santos P, Barbuto J. Tolerogenic IDO(+) Dendritic Cells Are Induced by PD-1-Expressing Mast Cells. Front Immunol. 2016;7:9 pubmed publisher |
| Carbotti G, Barisione G, Airoldi I, Mezzanzanica D, Bagnoli M, Ferrero S, et al. IL-27 induces the expression of IDO and PD-L1 in human cancer cells. Oncotarget. 2015;6:43267-80 pubmed publisher |
| Wang W, Yen M, Liu K, Hsu P, Lin M, Chen P, et al. Interleukin-25 Mediates Transcriptional Control of PD-L1 via STAT3 in Multipotent Human Mesenchymal Stromal Cells (hMSCs) to Suppress Th17 Responses. Stem Cell Reports. 2015;5:392-404 pubmed publisher |
| Martin A, Nirschl T, Nirschl C, Francica B, Kochel C, Van Bokhoven A, et al. Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance. Prostate Cancer Prostatic Dis. 2015;18:325-32 pubmed publisher |
| Teixidó C, Karachaliou N, González Cao M, Morales Espinosa D, Rosell R. Assays for predicting and monitoring responses to lung cancer immunotherapy. Cancer Biol Med. 2015;12:87-95 pubmed publisher |
| Baban B, Liu J, Qin X, Weintraub N, Mozaffari M. Upregulation of Programmed Death-1 and Its Ligand in Cardiac Injury Models: Interaction with GADD153. PLoS ONE. 2015;10:e0124059 pubmed publisher |
| Buddhisa S, Rinchai D, Ato M, Bancroft G, Lertmemongkolchai G. Programmed death ligand 1 on Burkholderia pseudomallei-infected human polymorphonuclear neutrophils impairs T cell functions. J Immunol. 2015;194:4413-21 pubmed publisher |
| Mimura K, Kua L, Shiraishi K, Kee Siang L, Shabbir A, Komachi M, et al. Inhibition of mitogen-activated protein kinase pathway can induce upregulation of human leukocyte antigen class I without PD-L1-upregulation in contrast to interferon-? treatment. Cancer Sci. 2014;105:1236-44 pubmed publisher |
| Tjin E, Krebbers G, Meijlink K, van de Kasteele W, Rosenberg E, Sanders J, et al. Immune-escape markers in relation to clinical outcome of advanced melanoma patients following immunotherapy. Cancer Immunol Res. 2014;2:538-46 pubmed publisher |
| Pen J, Keersmaecker B, Heirman C, Corthals J, Liechtenstein T, Escors D, et al. Interference with PD-L1/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells. Gene Ther. 2014;21:262-71 pubmed publisher |
| Legat A, Speiser D, Pircher H, Zehn D, Fuertes Marraco S. Inhibitory Receptor Expression Depends More Dominantly on Differentiation and Activation than "Exhaustion" of Human CD8?T Cells. Front Immunol. 2013;4:455 pubmed publisher |
| Baglio F, Saresella M, Preti M, Cabinio M, Griffanti L, Marventano I, et al. Neuroinflammation and brain functional disconnection in Alzheimer's disease. Front Aging Neurosci. 2013;5:81 pubmed publisher |
| Maine C, Aziz N, Chatterjee J, Hayford C, Brewig N, Whilding L, et al. Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer. Cancer Immunol Immunother. 2014;63:215-24 pubmed publisher |
| Seliger B. B7-H abnormalities in melanoma and clinical relevance. Methods Mol Biol. 2014;1102:367-80 pubmed publisher |
| Wrangle J, Wang W, Koch A, Easwaran H, Mohammad H, Vendetti F, et al. Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine. Oncotarget. 2013;4:2067-79 pubmed |
| Esch K, Juelsgaard R, Martínez P, Jones D, Petersen C. Programmed death 1-mediated T cell exhaustion during visceral leishmaniasis impairs phagocyte function. J Immunol. 2013;191:5542-50 pubmed publisher |
| Luheshi N, Davies G, Poon E, Wiggins K, McCourt M, Legg J. Th1 cytokines are more effective than Th2 cytokines at licensing anti-tumour functions in CD40-activated human macrophages in vitro. Eur J Immunol. 2014;44:162-72 pubmed publisher |
| Haile S, Dalal S, Clements V, Tamada K, Ostrand Rosenberg S. Soluble CD80 restores T cell activation and overcomes tumor cell programmed death ligand 1-mediated immune suppression. J Immunol. 2013;191:2829-36 pubmed publisher |
| Kared H, Fabre T, Bedard N, Bruneau J, Shoukry N. Galectin-9 and IL-21 mediate cross-regulation between Th17 and Treg cells during acute hepatitis C. PLoS Pathog. 2013;9:e1003422 pubmed publisher |
| Singh A, Mohan A, Dey A, Mitra D. Inhibiting the programmed death 1 pathway rescues Mycobacterium tuberculosis-specific interferon ?-producing T cells from apoptosis in patients with pulmonary tuberculosis. J Infect Dis. 2013;208:603-15 pubmed publisher |
| Bloch O, Crane C, Kaur R, Safaee M, Rutkowski M, Parsa A. Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages. Clin Cancer Res. 2013;19:3165-75 pubmed publisher |
| Méndez Reguera A, Pérez Montesinos G, Alcántara Hernández M, Martínez Estrada V, Cazarin Barrientos J, Rojas Espinosa O, et al. Pathogenic CCR6+ dendritic cells in the skin lesions of discoid lupus patients: a role for damage-associated molecular patterns. Eur J Dermatol. 2013;23:169-82 pubmed publisher |
| Huang G, Wen Q, Zhao Y, Gao Q, Bai Y. NF-?B plays a key role in inducing CD274 expression in human monocytes after lipopolysaccharide treatment. PLoS ONE. 2013;8:e61602 pubmed publisher |
| Sznol M, Chen L. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res. 2013;19:1021-34 pubmed publisher |
| Knol A, Nguyen J, Pandolfino M, Quereux G, Brocard A, Peuvrel L, et al. Tissue biomarkers in melanoma patients treated with TIL. PLoS ONE. 2012;7:e48729 pubmed publisher |
| Singh A, Dey A, Mohan A, Sharma P, Mitra D. Foxp3+ regulatory T cells among tuberculosis patients: impact on prognosis and restoration of antigen specific IFN-? producing T cells. PLoS ONE. 2012;7:e44728 pubmed publisher |
| Severa M, Giacomini E, Gafa V, Anastasiadou E, Rizzo F, Corazzari M, et al. EBV stimulates TLR- and autophagy-dependent pathways and impairs maturation in plasmacytoid dendritic cells: implications for viral immune escape. Eur J Immunol. 2013;43:147-58 pubmed publisher |
| Lichtenegger F, Mueller K, Otte B, Beck B, Hiddemann W, Schendel D, et al. CD86 and IL-12p70 are key players for T helper 1 polarization and natural killer cell activation by Toll-like receptor-induced dendritic cells. PLoS ONE. 2012;7:e44266 pubmed publisher |
| Li Y, Wang J, Li C, Ke X. Contribution of PD-L1 to oncogenesis of lymphoma and its RNAi-based targeting therapy. Leuk Lymphoma. 2012;53:2015-23 pubmed publisher |
| Ou J, Wiedeman A, Stevens A. TNF-? and TGF-? counter-regulate PD-L1 expression on monocytes in systemic lupus erythematosus. Sci Rep. 2012;2:295 pubmed publisher |
| Ioannou M, Alissafi T, Lazaridis I, Deraos G, Matsoukas J, Gravanis A, et al. Crucial role of granulocytic myeloid-derived suppressor cells in the regulation of central nervous system autoimmune disease. J Immunol. 2012;188:1136-46 pubmed publisher |
| Fujimura T, Ring S, Umansky V, Mahnke K, Enk A. Regulatory T cells stimulate B7-H1 expression in myeloid-derived suppressor cells in ret melanomas. J Invest Dermatol. 2012;132:1239-46 pubmed publisher |
| Wang B, Bao J, Wang J, Wang Y, Jiang M, Xing M, et al. Immunostaining of PD-1/PD-Ls in liver tissues of patients with hepatitis and hepatocellular carcinoma. World J Gastroenterol. 2011;17:3322-9 pubmed publisher |
| Muthumani K, Shedlock D, Choo D, Fagone P, Kawalekar O, Goodman J, et al. HIV-mediated phosphatidylinositol 3-kinase/serine-threonine kinase activation in APCs leads to programmed death-1 ligand upregulation and suppression of HIV-specific CD8 T cells. J Immunol. 2011;187:2932-43 pubmed publisher |
| Kozako T, Yoshimitsu M, Akimoto M, White Y, Matsushita K, Soeda S, et al. Programmed death-1 (PD-1)/PD-1 ligand pathway-mediated immune responses against human T-lymphotropic virus type 1 (HTLV-1) in HTLV-1-associated myelopathy/tropical spastic paraparesis and carriers with autoimmune disorders. Hum Immunol. 2011;72:1001-6 pubmed publisher |
| Zheng J, Umikawa M, Zhang S, Huynh H, Silvany R, Chen B, et al. Ex vivo expanded hematopoietic stem cells overcome the MHC barrier in allogeneic transplantation. Cell Stem Cell. 2011;9:119-30 pubmed publisher |
| Kim Y, Park S, Broxmeyer H. Phagocytosis, a potential mechanism for myeloid-derived suppressor cell regulation of CD8+ T cell function mediated through programmed cell death-1 and programmed cell death-1 ligand interaction. J Immunol. 2011;187:2291-301 pubmed publisher |
| Morbach H, Wiegering V, Richl P, Schwarz T, Suffa N, Eichhorn E, et al. Activated memory B cells may function as antigen-presenting cells in the joints of children with juvenile idiopathic arthritis. Arthritis Rheum. 2011;63:3458-66 pubmed publisher |
| Figel A, Brech D, Prinz P, Lettenmeyer U, Eckl J, Turqueti Neves A, et al. Human renal cell carcinoma induces a dendritic cell subset that uses T-cell crosstalk for tumor-permissive milieu alterations. Am J Pathol. 2011;179:436-51 pubmed publisher |
| Zhao Q, Xiao X, Wu Y, Wei Y, Zhu L, Zhou J, et al. Interleukin-17-educated monocytes suppress cytotoxic T-cell function through B7-H1 in hepatocellular carcinoma patients. Eur J Immunol. 2011;41:2314-22 pubmed publisher |
| Haile S, Bosch J, Agu N, Zeender A, Somasundaram P, Srivastava M, et al. Tumor cell programmed death ligand 1-mediated T cell suppression is overcome by coexpression of CD80. J Immunol. 2011;186:6822-9 pubmed publisher |
| Andorsky D, Yamada R, Said J, Pinkus G, Betting D, Timmerman J. Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Clin Cancer Res. 2011;17:4232-44 pubmed publisher |
| Saresella M, Calabrese E, Marventano I, Piancone F, Gatti A, Farina E, et al. A potential role for the PD1/PD-L1 pathway in the neuroinflammation of Alzheimer's disease. Neurobiol Aging. 2012;33:624.e11-22 pubmed publisher |
| Frigola X, Inman B, Lohse C, Krco C, Cheville J, Thompson R, et al. Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma. Clin Cancer Res. 2011;17:1915-23 pubmed publisher |
| Zhang Y, Li J, Lou J, Zhou Y, Bo L, Zhu J, et al. Upregulation of programmed death-1 on T cells and programmed death ligand-1 on monocytes in septic shock patients. Crit Care. 2011;15:R70 pubmed publisher |
| Banerjee S, Lin C, Skinner K, Schiffhauer L, Peacock J, Hicks D, et al. Heat shock protein 27 differentiates tolerogenic macrophages that may support human breast cancer progression. Cancer Res. 2011;71:318-27 pubmed publisher |
| van de Laar L, van den Bosch A, van der Kooij S, Janssen H, Coffer P, van Kooten C, et al. A nonredundant role for canonical NF-?B in human myeloid dendritic cell development and function. J Immunol. 2010;185:7252-61 pubmed publisher |
| Greenough T, Campellone S, Brody R, Jain S, Sanchez Merino V, Somasundaran M, et al. Programmed Death-1 expression on Epstein Barr virus specific CD8+ T cells varies by stage of infection, epitope specificity, and T-cell receptor usage. PLoS ONE. 2010;5:e12926 pubmed publisher |
| Deshpande M, Tipnis S, Shetty P, Ghosh D, Viswanathan C, Majumdar A. Immunologic properties of human dermal fibroblasts. Hum Immunol. 2010;71:1089-98 pubmed publisher |
| Hsu M, Hsiao J, Chang K, Wu Y, Su I, Jin Y, et al. Increase of programmed death-1-expressing intratumoral CD8 T cells predicts a poor prognosis for nasopharyngeal carcinoma. Mod Pathol. 2010;23:1393-403 pubmed publisher |
| Wu Y, Lin C, Cheng K, Lin C, Wang Y, Lin I, et al. Increased programmed death-ligand-1 expression in human gastric epithelial cells in Helicobacter pylori infection. Clin Exp Immunol. 2010;161:551-9 pubmed publisher |
| Ghebeh H, Lehe C, Barhoush E, Al Romaih K, Tulbah A, Al Alwan M, et al. Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7-H1 as an anti-apoptotic molecule. Breast Cancer Res. 2010;12:R48 pubmed publisher |
| Alvarez I, Pasquinelli V, Jurado J, Abbate E, Musella R, de la Barrera S, et al. Role played by the programmed death-1-programmed death ligand pathway during innate immunity against Mycobacterium tuberculosis. J Infect Dis. 2010;202:524-32 pubmed publisher |
| Plege A, Borns K, Beer L, Baars W, Klempnauer J, Schwinzer R. Downregulation of cytolytic activity of human effector cells by transgenic expression of human PD-ligand-1 on porcine target cells. Transpl Int. 2010;23:1293-300 pubmed publisher |
| Kleijwegt F, Laban S, Duinkerken G, Joosten A, Zaldumbide A, Nikolic T, et al. Critical role for TNF in the induction of human antigen-specific regulatory T cells by tolerogenic dendritic cells. J Immunol. 2010;185:1412-8 pubmed publisher |
| Benson D, Bakan C, Mishra A, Hofmeister C, Efebera Y, Becknell B, et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood. 2010;116:2286-94 pubmed publisher |
| Matsuzaki J, Gnjatic S, Mhawech Fauceglia P, Beck A, Miller A, Tsuji T, et al. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A. 2010;107:7875-80 pubmed publisher |
| Yamada Y, Sugita S, Horie S, Yamagami S, Mochizuki M. Mechanisms of immune suppression for CD8+ T cells by human corneal endothelial cells via membrane-bound TGFbeta. Invest Ophthalmol Vis Sci. 2010;51:2548-57 pubmed publisher |
| Zhang L, Bertucci A, Ramsey Goldman R, Burt R, Datta S. Regulatory T cell (Treg) subsets return in patients with refractory lupus following stem cell transplantation, and TGF-beta-producing CD8+ Treg cells are associated with immunological remission of lupus. J Immunol. 2009;183:6346-58 pubmed publisher |
| Kvistborg P, Boegh M, Pedersen A, Claesson M, Zocca M. Fast generation of dendritic cells. Cell Immunol. 2009;260:56-62 pubmed publisher |
| Xie Z, Chen Y, Zhao S, Yang Z, Yao X, Guo S, et al. Intrahepatic PD-1/PD-L1 up-regulation closely correlates with inflammation and virus replication in patients with chronic HBV infection. Immunol Invest. 2009;38:624-38 pubmed |
| Pedersen A, Holmstrøm K, Jensen S, Fuchs D, Rasmussen S, Kvistborg P, et al. Phenotypic and functional markers for 1alpha,25-dihydroxyvitamin D(3)-modified regulatory dendritic cells. Clin Exp Immunol. 2009;157:48-59 pubmed publisher |
| Wilcox R, Feldman A, Wada D, Yang Z, Comfere N, Dong H, et al. B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood. 2009;114:2149-58 pubmed publisher |
| Kuang D, Zhao Q, Peng C, Xu J, Zhang J, Wu C, et al. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med. 2009;206:1327-37 pubmed publisher |
| Zhang Z, Jin B, Zhang J, Xu B, Wang H, Shi M, et al. Dynamic decrease in PD-1 expression correlates with HBV-specific memory CD8 T-cell development in acute self-limited hepatitis B patients. J Hepatol. 2009;50:1163-73 pubmed publisher |
| Gehring A, Ho Z, Tan A, Aung M, Lee K, Tan K, et al. Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma. Gastroenterology. 2009;137:682-90 pubmed publisher |
| Fourcade J, Kudela P, Sun Z, Shen H, Land S, Lenzner D, et al. PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J Immunol. 2009;182:5240-9 pubmed publisher |
| Yao Y, Tao R, Wang X, Wang Y, Mao Y, Zhou L. B7-H1 is correlated with malignancy-grade gliomas but is not expressed exclusively on tumor stem-like cells. Neuro Oncol. 2009;11:757-66 pubmed publisher |
| Gong A, Zhou R, Hu G, Li X, Splinter P, O Hara S, et al. MicroRNA-513 regulates B7-H1 translation and is involved in IFN-gamma-induced B7-H1 expression in cholangiocytes. J Immunol. 2009;182:1325-33 pubmed |
| Bertsias G, Nakou M, Choulaki C, Raptopoulou A, Papadimitraki E, Goulielmos G, et al. Genetic, immunologic, and immunohistochemical analysis of the programmed death 1/programmed death ligand 1 pathway in human systemic lupus erythematosus. Arthritis Rheum. 2009;60:207-18 pubmed publisher |
| Liang M, Yang H, Fu J. Nimesulide inhibits IFN-gamma-induced programmed death-1-ligand 1 surface expression in breast cancer cells by COX-2 and PGE2 independent mechanisms. Cancer Lett. 2009;276:47-52 pubmed publisher |
| Kinter A, Godbout E, McNally J, Sereti I, Roby G, O Shea M, et al. The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J Immunol. 2008;181:6738-46 pubmed |
| Wang X, Zhang Z, Zhang S, Fu J, Yao J, Jiao Y, et al. B7-H1 up-regulation impairs myeloid DC and correlates with disease progression in chronic HIV-1 infection. Eur J Immunol. 2008;38:3226-36 pubmed publisher |
| Kozako T, Yoshimitsu M, Fujiwara H, Masamoto I, Horai S, White Y, et al. PD-1/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patients. Leukemia. 2009;23:375-82 pubmed publisher |
| Sugita S, Usui Y, Horie S, Futagami Y, Yamada Y, Ma J, et al. Human corneal endothelial cells expressing programmed death-ligand 1 (PD-L1) suppress PD-1+ T helper 1 cells by a contact-dependent mechanism. Invest Ophthalmol Vis Sci. 2009;50:263-72 pubmed publisher |
| Zhang J, Zhang Z, Jin B, Zhang S, Zhou C, Fu J, et al. Cutting edge: programmed death-1 up-regulation is involved in the attrition of cytomegalovirus-specific CD8+ T cells in acute self-limited hepatitis B virus infection. J Immunol. 2008;181:3741-4 pubmed |
| Butte M, Pena Cruz V, Kim M, Freeman G, Sharpe A. Interaction of human PD-L1 and B7-1. Mol Immunol. 2008;45:3567-72 pubmed publisher |
| Jaehn P, Zaenker K, Schmitz J, Dzionek A. Functional dichotomy of plasmacytoid dendritic cells: antigen-specific activation of T cells versus production of type I interferon. Eur J Immunol. 2008;38:1822-32 pubmed publisher |
| Taglauer E, Trikhacheva A, Slusser J, Petroff M. Expression and function of PDCD1 at the human maternal-fetal interface. Biol Reprod. 2008;79:562-9 pubmed publisher |
| Lafon M, Mégret F, Meuth S, Simon O, Velandia Romero M, Lafage M, et al. Detrimental contribution of the immuno-inhibitor B7-H1 to rabies virus encephalitis. J Immunol. 2008;180:7506-15 pubmed |
| Yang W, Chen P, Li H, Alizadeh H, Niederkorn J. PD-L1: PD-1 interaction contributes to the functional suppression of T-cell responses to human uveal melanoma cells in vitro. Invest Ophthalmol Vis Sci. 2008;49:2518-25 pubmed publisher |
| Ghebeh H, Barhoush E, Tulbah A, Elkum N, Al Tweigeri T, Dermime S. FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy. BMC Cancer. 2008;8:57 pubmed publisher |
| Onlamoon N, Rogers K, Mayne A, Pattanapanyasat K, Mori K, Villinger F, et al. Soluble PD-1 rescues the proliferative response of simian immunodeficiency virus-specific CD4 and CD8 T cells during chronic infection. Immunology. 2008;124:277-93 pubmed publisher |
| Gröschel S, Piggott K, Vaglio A, Ma Krupa W, Singh K, Goronzy J, et al. TLR-mediated induction of negative regulatory ligands on dendritic cells. J Mol Med (Berl). 2008;86:443-55 pubmed publisher |
| Waggoner S, Hall C, Hahn Y. HCV core protein interaction with gC1q receptor inhibits Th1 differentiation of CD4+ T cells via suppression of dendritic cell IL-12 production. J Leukoc Biol. 2007;82:1407-19 pubmed |
| Ghebeh H, Tulbah A, Mohammed S, Elkum N, Bin Amer S, Al Tweigeri T, et al. Expression of B7-H1 in breast cancer patients is strongly associated with high proliferative Ki-67-expressing tumor cells. Int J Cancer. 2007;121:751-8 pubmed |
| Perrot I, Blanchard D, Freymond N, Isaac S, Guibert B, Pacheco Y, et al. Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage. J Immunol. 2007;178:2763-9 pubmed |
| Ghebeh H, Mohammed S, Al Omair A, Qattan A, Lehe C, Al Qudaihi G, et al. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia. 2006;8:190-8 pubmed |
| Chen Y, Zhang J, Li J, Zou L, Zhao T, Tang Y, et al. Expression of B7-H1 in inflammatory renal tubular epithelial cells. Nephron Exp Nephrol. 2006;102:e81-92 pubmed |
| Methe H, Nugent H, Groothuis A, Seifert P, Sayegh M, Edelman E. Matrix embedding alters the immune response against endothelial cells in vitro and in vivo. Circulation. 2005;112:I89-95 pubmed |
| Azam P, Peiffer J, Chamousset D, Tissier M, Bonnet P, Vian L, et al. The cytokine-dependent MUTZ-3 cell line as an in vitro model for the screening of contact sensitizers. Toxicol Appl Pharmacol. 2006;212:14-23 pubmed |
| Wilmotte R, Burkhardt K, Kindler V, Belkouch M, Dussex G, Tribolet N, et al. B7-homolog 1 expression by human glioma: a new mechanism of immune evasion. Neuroreport. 2005;16:1081-5 pubmed |
| Ohigashi Y, Sho M, Yamada Y, Tsurui Y, Hamada K, Ikeda N, et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res. 2005;11:2947-53 pubmed |
| Saudemont A, Jouy N, Hetuin D, Quesnel B. NK cells that are activated by CXCL10 can kill dormant tumor cells that resist CTL-mediated lysis and can express B7-H1 that stimulates T cells. Blood. 2005;105:2428-35 pubmed |
| Kanai T, Totsuka T, Uraushihara K, Makita S, Nakamura T, Koganei K, et al. Blockade of B7-H1 suppresses the development of chronic intestinal inflammation. J Immunol. 2003;171:4156-63 pubmed |
| Freeman G, Long A, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192:1027-34 pubmed |
| Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 1999;5:1365-9 pubmed |
